Trials / Completed
CompletedNCT00666900
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 366 (actual)
- Sponsor
- Dow Pharmaceutical Sciences · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Low Strength IDP-107 | Once a day for 12 weeks |
| DRUG | High Strength IDP-107 | Once a day for 12 weeks |
| DRUG | Placebo Comparator | Once a day for 12 weeks |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-03-01
- Completion
- 2009-09-01
- First posted
- 2008-04-25
- Last updated
- 2012-02-20
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00666900. Inclusion in this directory is not an endorsement.